Multi-billion-dollar potential for Innovent, Roche collaboration

9 June 2020
asia_asian_lab_research_biotech_big

A new strategic research collaboration between Swiss cancer giant Roche (ROG: SIX) and Chinese biotech Innovent Biologics (HKEX: 01801) has sent shares in the latter climbing 4% in Hong Kong.

Based in Suzhou, Innovent is focused on developing and commercializing therapies in cancer, metabolic, autoimmune and other major diseases.

The firm brought in revenues of over 1 billion renminbi ($141 million) in 2019, driven by its only approved product, Tyvyt (sintilimab injection), a Hodgkin's lymphoma therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology